ERA stands for Endometrial Receptivity Analysis, a genetic test used during IVF to determine whether your uterine lining is ready to receive an embryo at the time your doctor would normally schedule a transfer. The test analyzes the activity of 238 genes in a small tissue sample from your uterus, then classifies your lining as “receptive” or “non-receptive” on that particular day. The idea is straightforward: if your window of implantation is shifted earlier or later than expected, transferring an embryo at the standard time means the embryo arrives when the lining isn’t ready for it.
How the Test Works
Your uterine lining goes through precise hormonal changes each cycle to prepare for a potential pregnancy. There’s a narrow window, typically lasting about 24 to 48 hours, when the lining is most receptive to an embryo. In a standard frozen embryo transfer, doctors assume this window falls on the fifth day after starting progesterone (about 120 hours of progesterone exposure). For most people, that timing is correct. But for some, the window opens a day earlier or a day later.
ERA uses a technology called transcriptomics, which measures which genes are turned on or off in your endometrial tissue at a specific moment. The test reads the activity pattern of 238 genes known to be involved in making the lining receptive, then runs that pattern through a computational model. The model returns one of three results: receptive, pre-receptive (your window hasn’t opened yet), or post-receptive (your window has already passed).
What the Biopsy Involves
The ERA requires an endometrial biopsy, which is done during a “mock” cycle rather than a cycle where you’re actually transferring an embryo. Your doctor prepares your lining with hormones just as they would for a real frozen embryo transfer, then performs the biopsy at the 120-hour progesterone mark. A thin catheter is passed through the cervix to collect a small sample of tissue from the uterine lining. The procedure takes a few minutes and is often compared to a sharp menstrual cramp. No anesthesia is typically needed, though discomfort varies.
The tissue sample is sent to Igenomix, the company that developed and runs the ERA test. Results usually come back within about two weeks.
What the Results Mean
If your result comes back “receptive,” it means your window of implantation lines up with the standard transfer timing. No adjustment is needed. If the result is “pre-receptive,” your lining needs more progesterone exposure before it’s ready, and your doctor will shift the transfer to a later day. A “post-receptive” result means the window has already closed by that point, so the transfer would be moved earlier.
When the first biopsy shows a non-receptive result, a second ERA biopsy is sometimes performed on the adjusted day to confirm that the new timing hits the receptive window. Once the correct day is identified, all future embryo transfers are scheduled according to that personalized timing. This approach is called a personalized embryo transfer, or pET.
Who Typically Gets an ERA
ERA testing is most commonly recommended for people experiencing recurrent implantation failure, meaning good-quality embryos have been transferred multiple times without resulting in pregnancy. A common threshold used by fertility clinics is two or more failed transfers involving at least three high-quality embryos (or two chromosomally normal embryos), with at least one of those being a frozen embryo transfer.
Some clinics also offer it to patients who want to optimize their first transfer, particularly if they have a limited number of embryos and want to reduce the chance of a failed cycle. However, the strongest rationale for the test remains recurrent failure, where there’s reason to suspect the transfer timing itself may be the problem rather than embryo quality.
The Timing Question
One study examining ERA results at different progesterone exposure times illustrates why timing matters so much. When biopsies were taken on day six of progesterone (one day later than the standard day five), only about 24% of samples came back as receptive. Roughly 74% were pre-receptive, and about 2% were post-receptive. This doesn’t mean most people have a displaced window. It shows that even a single day of difference in when the biopsy is taken dramatically changes the gene expression profile, which is exactly the sensitivity the test is designed to detect.
Does ERA Improve Pregnancy Rates?
This is the most debated question surrounding the test. Early studies from the team that developed ERA showed promising results, particularly in patients with recurrent implantation failure. The original research demonstrated that guiding embryo transfers based on ERA results could lead to pregnancies in patients who had previously failed multiple cycles, suggesting their window of implantation had genuinely been displaced.
However, larger and more rigorous studies have produced mixed findings. A nested diagnostic accuracy study published in Fertility and Sterility evaluated the test within a randomized clinical trial and raised questions about how consistently it improves outcomes across broader patient populations. The core issue is that most patients, even those with implantation failure, turn out to have a receptive result at standard timing. For those patients, ERA doesn’t change anything about the transfer plan, so it functions more as a rule-out test than a treatment.
For the subset of patients whose window genuinely is displaced, adjusting transfer timing based on ERA can be meaningful. The challenge is that this subset appears to be relatively small, and there isn’t yet strong consensus from major reproductive medicine organizations on whether ERA should be used routinely or reserved for specific clinical situations.
Cost and Practical Considerations
ERA testing typically costs between $800 and $1,500 for the test itself, plus the cost of the mock cycle medications and monitoring appointments. Insurance rarely covers it. Because it requires a dedicated mock cycle, it also adds roughly one month to your treatment timeline before you can proceed to an actual embryo transfer.
If a second biopsy is needed to confirm adjusted timing, that adds another mock cycle and another round of costs. For patients weighing whether to pursue ERA, the practical tradeoff is the financial and time investment of testing versus the potential benefit of avoiding another failed transfer with a limited supply of embryos.